SCOR’s 2011 Registration Document (“Document de Référence”) was filed with the French financial market authority, the Autorité des marchés financiers (AMF), on 8 March 2012.
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.
The subject of this note is to propose a set of analytical methods to derive a “closed-form solution” for MVM for a Non-Life insurance company, from a theoretical model first, and then to fit this model to a given set
Kidney donation is becoming increasingly common throughout the world, with the United States and Japan leading the way in this field, and the studies referenced in this Newsletter came from these two countries.
Kidney donation is becoming increasingly common throughout the world, with the United States and Japan leading the way in this field, and the studies referenced in this Newsletter came from these two countries.
Kidney donation is becoming increasingly common throughout the world, with the United States and Japan leading the way in this field, and the studies referenced in this Newsletter came from these two countries.
SCOR's 2012 renewals.
SCOR successfully concludes the January 1, 2012 renewals: 13.9% growth, satisfactory pricing conditions (+2%) and expected technical profitability
SCOR successfully concludes the January 1, 2012 renewals: 13.9% growth, satisfactory pricing conditions (+2%) and expected technical profitability.
